Brief: Angion And Vifor Pharma Report Topline Results From Phase 2 Guard Trial Of ANG-3777 In Cardiac Surgery-Associated Acute Kidney Injury

Elicio Therapeutics

09/12/2021 21:47

Dec 9 (Reuters) - Angion Biomedica Corp  ANGN.O :
    * ANGION AND VIFOR PHARMA REPORT TOPLINE RESULTS FROM PHASE
2
GUARD TRIAL OF ANG-3777 IN CARDIAC SURGERY-ASSOCIATED ACUTE
KIDNEY INJURY
    * ANGION BIOMEDICA CORP - TRIAL DID NOT MEET PRIMARY
ENDPOINT OF
PERCENTAGE INCREASE IN SERUM CREATININE BASED UPON AREA UNDER
CURVE
    * ANGION BIOMEDICA CORP - CO AND VIFOR PHARMA CONTINUE TO
REVIEW
DATA BASED ON SIGNAL DEMONSTRATED IN CLINICALLY RELEVANT MAKE90
SECONDARY ENDPOINT

Source text for Eikon:  ID:nGNX2P5CCS 
Further company coverage:  ANGN.O